June 2020, Drugs Monitor, Page 2

(23 June 2020) Dexamethasone- reduced deaths by one-third in patients receiving invasive mechanical ventilation

June 23, 2020

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1 Reports from the preliminary results of RECOVERY trial [The RECOVERY trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936)]for the comparison of dexamethasone 6 mg given once daily for… Continue reading "(23 June 2020) Dexamethasone- reduced deaths by one-third in patients receiving invasive mechanical ventilation"

(22 June 2020) Tocilizumab- improved oxygenation and inflammatory biomarkers

June 22, 2020

Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes https://doi.org/10.1016/j.chest.2020.06.006 Among 239 patients, median age was 64 years; 36% and 19% were Black and Hispanic, respectively. Hospital census increased exponentially, yet MV census did not.… Continue reading "(22 June 2020) Tocilizumab- improved oxygenation and inflammatory biomarkers"

(22 June 2020) Hydroxychloroquine- no significant reduction of the risk of unfavorable outcomes

June 22, 2020

Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital https://www.ncbi.nlm.nih.gov/research/coronavirus/publication/32556143 In an observational, retrospective cohort study involving hospitalized adult patients with confirmed, mild to severe Covid-19 in a French university… Continue reading "(22 June 2020) Hydroxychloroquine- no significant reduction of the risk of unfavorable outcomes"

(20 June 2020) Hydroxychloroquine- no evidence for efficacy of HCQ or HCQ combined with AZI on 28-day mortality

June 20, 2020

Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France https://doi.org/10.1101/2020.06.16.20132597 In a retrospective study involving large non-selected population of inpatients hospitalized for COVID-19 infection in… Continue reading "(20 June 2020) Hydroxychloroquine- no evidence for efficacy of HCQ or HCQ combined with AZI on 28-day mortality"

(17 June 2020) Interferon beta1- significant recovery in 14 days with IFN-β-1a and conventional therapy

June 19, 2020

Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial https://www.sciencedirect.com/science/article/pii/S1567576920312893?via%3Dihub In this prospective non-controlled trial (IRCT20151227025726N12), 20 patients were included. They received IFN-β-1a at a dose of 44 µg subcutaneously every other day up to 10 days. All… Continue reading "(17 June 2020) Interferon beta1- significant recovery in 14 days with IFN-β-1a and conventional therapy"

(16 June 2020) Tocilizumab- Early administration of tocilizumab below FiO2 ≤0.5% significantly more effective

June 17, 2020

Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late https://doi.org/10.1101/2020.06.13.20130088 In a compassionate-use basis to patients with SSP hospitalized (excluding intensive care and intubated cases) who required oxygen support to have a saturation >93%. Primary… Continue reading "(16 June 2020) Tocilizumab- Early administration of tocilizumab below FiO2 ≤0.5% significantly more effective"

(12 June 2020) Lopinavir/ritonavir- No significant benefit of combined LPV/r and HCQ treatment of COVID-19

June 13, 2020

Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study. https://doi.org/10.1101/2020.06.05.20123299 The aim of this retrospective intent-to-treat analysis of the hospitalized patients was to compare the rate of clinical improvement between… Continue reading "(12 June 2020) Lopinavir/ritonavir- No significant benefit of combined LPV/r and HCQ treatment of COVID-19"

(12 June 2020) Tocilizumab- associated with rapid improvement in both CRP and lymphocyte counts and in clinical indices

June 13, 2020

Temporal clinical and laboratory response to interleukin-6 receptor blockade with Tocilizumab in 89 hospitalized patients with COVID-19 pneumonia https://doi.org/10.1101/2020.06.12.20122374 Eighty nine patients with COVID-19 pneumonia and heightened systemic inflammation (elevated serum C reactive protein and interleukin-6 levels) were treated with… Continue reading "(12 June 2020) Tocilizumab- associated with rapid improvement in both CRP and lymphocyte counts and in clinical indices"

(10 June 2020) Remdesivir- virus titers reduced in 12 hrs after the first treatment administration in rhesus macaque model

June 11, 2020

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 https://doi.org/10.1038/s41586-020-2423-5 The efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection was investigated. In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of… Continue reading "(10 June 2020) Remdesivir- virus titers reduced in 12 hrs after the first treatment administration in rhesus macaque model"

(09 June 2020) Arbidol- combined with adjuvant therapy could normalize patient’s temperature faster

June 11, 2020

A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19 https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.26142 The study included 62 patients with COVID-19 admitted to the First Hospital of Jiaxing from January to March, 2020, and all patients were divided into the… Continue reading "(09 June 2020) Arbidol- combined with adjuvant therapy could normalize patient’s temperature faster"

Month: June 2020